Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease

Executive Summary

• Arch Biopartners announced peer‑reviewed publication identifying interleukin‑32 (IL‑32) as a novel lipid droplet‑associated cytokine linked to tubular injury in diabetic kidney disease (DKD).
• The discovery supports Arch’s CKD platform and underpins plans to advance an IL‑32‑targeted drug candidate toward an IND filing with the U.S. FDA within the next 12–18 months.
• The company highlighted its broader pipeline (LSALT peptide, cilastatin, CKD platform) and reiterated ongoing Phase II trials for acute kidney injury indications.

Key Details

• Publication: “Spatial transcriptomics identifies IL‑32 as a lipid droplet‑associated cytokine linked to tubular injury in human diabetic kidney disease,” Inflammation Research, Vol. 75, Article 33 (2026). DOI: https://doi.org/10.1007/s00011-026-02192-y.
• Research Findings: Human DKD kidney tissue shows accumulation of lipid droplets coated with IL‑32; this cytokine is believed to drive tubular injury and inflammation.
• Scientific Team: Led by Dr. Justin Chun, University of Calgary; work supported by the Canadian Institutes of Health Research and the Canada Foundation for Innovation.
• Strategic Implication: IL‑32 identified as a potential therapeutic target linking metabolic dysregulation and inflammation in DKD, providing a novel pathway distinct from existing SGLT2 inhibitors and GLP‑1 agonists.
• Future Development Plan:
• Conduct in vivo proof‑of‑concept studies.
• Optimize lead candidate targeting IL‑32.
• Target IND submission to the FDA within 12–18 months.
• Pipeline Context:
• LSALT peptide – Phase II trial for cardiac surgery‑associated AKI.
• Cilastatin – Repurposed drug in Phase II trial for toxin‑induced AKI.
• CKD Platform – Includes IL‑32 program and other next‑generation therapeutics for chronic kidney disease.
• Company Metrics (non‑material): 66,933,289 common shares outstanding.

Notable Quotes

“IL‑32 is a LD‑associated cytokine upregulated during tubular injury that represents a potential link between lipid dysregulation, inflammation and progression in human DKD,” – Authors of the publication.